The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-19. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
In contrast, systemic anatomy is the study of the structures that make up a discrete body system—that is, a group of structures that work together to perform a unique body function, such as the digestive system. Anatomy can be studied using both invasive and non-invasive methods with the goal of obtaining information about the structure and organization of organs and systems. Methods used include dissection, in which a body is opened and its organs studied, and endoscopy, in which a video camera-equipped instrument is inserted through a small incision in the body wall and used to explore the internal organs and other structures. Angiography, using X-rays or magnetic resonance angiography, is a method to visualize blood vessels. The term "anatomy" is commonly taken to refer to human anatomy. However, substantially similar structures and tissues are found throughout the rest of the animal kingdom, and the term also includes the anatomy of other animals. The term zootomy is also sometimes used to specifically refer to non-human animals. The structure and tissues of plants are of a dissimilar nature and they are studied in plant anatomy.
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy in tablet form, and molly in crystal form, is an entactogen with stimulant and minor psychedelic properties. MDMA was first synthesized in 1912 by Merck chemist Anton Köllisch. It was used to enhance psychotherapy beginning in the 1970s and became popular as a street drug in the 1980s. MDMA is commonly used by attendees of dance parties, raves, and electronic dance music festivals. Tablets sold as ecstasy may be mixed with other substances such as ephedrine, amphetamine, and methamphetamine. The lethal risk from one dose of MDMA is estimated to be from 1 death in 20,000 instances to 1 death in 50,000 instances. The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours. Short-term adverse effects include bruxism, blurred vision, sweating, and tachycardia, and extended use can also lead to addiction, amnesia, memory disorders, paranoia, and insomnia. Deaths have been reported due to increased body temperature and dehydration. MDMA acts primarily by increasing the release of the neurotransmitters serotonin, dopamine, and norepinephrine in parts of the brain. It belongs to the substituted amphetamine classes of drugs. MDMA is structurally similar to mescaline (a psychedelic), methamphetamine (a stimulant), as well as endogenous monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine.
=== „Ayda, Bär und Hase“ (2017) === The children's book „Ayda, Bär und Hase“ [Ayda, Bear and Rabbit] revisits the father-daughter relationship motif from the Neil Young book. The father, called Bâbâ, resembles other protagonists in Kermani's books (and the author himself): he has Iranian parents, lives in Cologne, and is a fan of the soccer team 1. FC Cologne and of Neil Young. The focus, however, is now on his five-year-old daughter Ayda, who is ill at ease with her small stature and befriends a bear and a rabbit who can talk. The book’s central themes include multicultural tolerance, the insight “that you can be happy even if not everything is perfect,” and overcoming fears together.
In 2005, the JECFA (Joint FAO/WHO Expert Committee On Food Additives) risk-assessment evaluation of ethyl carbamate concluded that the margin of exposure to ethyl carbamate from daily food and alcoholic beverages combined is of concern, and mitigation measures to reduce ethyl carbamate in some alcoholic beverages should continue. Ethyl carbamate exposure through alcoholic beverages has been discussed by multiple health authorities, while the cumulative daily exposure in the typical diet is also an issue of rising concern that merits closer observation. The Korean study concluded that "it would be desirable to closely monitor ethyl carbamate levels in Korean foods and find ways to reduce the daily intake." The following US regulators have mentioned urethane:
Sources: en.wikipedia.org
== Religious significance == In ancient Greek religion, the food of Zeus and the twelve Gods of Olympus was honey in the form of nectar and ambrosia. In the Hebrew Bible, the Promised Land (Canaan, the Land of Israel) is described 16 times as "the land of milk and honey" as a metaphor for its bounty. Of the 55 times the word "honey" appears in the Hebrew Bible, 16 are part of the expression "the land of milk and honey", and only twice is "honey" explicitly associated with bees, both being related to wild bees. Modern biblical researchers long considered that the original Hebrew word used in the Bible (דבש, devash) refers to the sweet syrup produced from figs or dates, because the domestication of the honey bee was completely undocumented through archaeology anywhere in the ancient Near East (excluding Egypt) at the time associated with the earlier biblical narratives (books of Exodus, Judges, Kings, etc.). In 2005, however, an apiary dating from the 10th century BC was found in Tel Rehov, Israel that contained 100 hives, estimated to produce half a ton of honey annually. This was, as of 2007, the only such finding made by archaeologists in the entire ancient Near East region, and it opens the possibility that biblical honey was indeed bee honey.
Louisville hotspot (23) 53°36′S 140°36′W, w= 1 az= 316° ±5° rate= 67 ±5 mm/yr Possibly related to the Ontong Java Plateau (125–120 Ma). Foundation hotspot/Ngatemato seamounts (57) 37°42′S 111°06′W, w= 1 az= 292° ±3° rate= 80 ±6 mm/yr Macdonald hotspot (24) 29°00′S 140°18′W, w= 1 az= 289° ±6° rate= 105 ±10 mm/yr North Austral/President Thiers (President Thiers Bank, 58) 25°36′S 143°18′W, w= (1.0) az= 293° ± 3° rate= 75 ±15 mm/yr Arago hotspot (Arago Seamount, 59) 23°24′S 150°42′W, w= 1 az= 296° ±4° rate= 120 ±20 mm/yr Maria/Southern Cook hotspot (Îles Maria, 60) 20°12′S 153°48′W, w= 0.8 az= 300° ±4° Samoa hotspot (35) 14°30′S 168°12′W, w= 0.8 az= 285°±5° rate= 95 ±20 mm/yr Crough hotspot (Crough Seamount, 61) 26°54′S 114°36′W, w= 0.8 az= 284° ± 2° Pitcairn hotspot (31) 25°24′S 129°18′W, w= 1 az= 293° ±3° rate= 90 ±15 mm/yr Society/Tahiti hotspot (38) 18°12′S 148°24′W, w= 0.8 az= 295°±5° rate= 109 ±10 mm/yr Marquesas hotspot (26) 10°30′S 139°00′W, w= 0.5 az= 319° ±8° rate= 93 ±7 mm/yr Caroline hotspot (4) 4°48′N 164°24′E, w= 1 az= 289° ±4° rate= 135 ±20 mm/yr Hawaii hotspot (12) 19°00′N 155°12′W, w= 1 az= 304° ±3° rate= 92 ±3 mm/yr Socorro/Revillagigedos hotspot (37) 19°00′N 111°00′W Guadalupe hotspot (11) 27°42′N 114°30′W, w= 0.8 az= 292° ±5° rate= 80 ±10 mm/yr Cobb hotspot (5) 46°00′N 130°06′W, w= 1 az= 321° ±5° rate= 43 ±3 mm/yr Bowie/Pratt-Welker hotspot (3) 53°00′N 134°48′W, w= 0.8 az= 306° ±4° rate= 40 ±20 mm/yr
==== Bapineuzumab ==== Bapineuzumab, a humanized anti-Aβ mAb, is directed against the N-terminus of Aβ. Phase II clinical trials of Bapineuzumab in mild to moderate AD patients resulted in reduced Aβ concentration in the brain. However, in patients with increased apolipoprotein (APOE) e4 carriers, Bapineuzumab treatment is also accompanied by vasogenic edema, a cytotoxic condition where the blood brain barrier has been disrupted thereby affecting white matter from excess accumulation of fluid from capillaries in intracellular and extracellular spaces of the brain. In Phase III clinical trials, Bapineuzumab showed promising positive effect on biomarkers of AD but failed to show effect on cognitive decline. Therefore, Bapineuzumab was discontinued after failing in the Phase III clinical trial.
==== High resolution melting analysis (HRM) ==== A further method to differentiate converted from unconverted bisulfite-treated DNA is using high-resolution melting analysis (HRM), a quantitative PCR-based technique initially designed to distinguish SNPs. The PCR amplicons are analyzed directly by temperature ramping and resulting liberation of an intercalating fluorescent dye during melting. The degree of methylation, as represented by the C-to-T content in the amplicon, determines the rapidity of melting and consequent release of the dye. This method allows direct quantitation in a single-tube assay, but assesses methylation in the amplified region as a whole rather than at specific CpG sites.
Dual diagnosis (also called co-occurring disorders (COD) or dual pathology) is the condition of having a mental illness and a comorbid substance use disorder. There is considerable debate surrounding the appropriateness of using a single category for a heterogeneous group of individuals with complex needs and a varied range of problems. The concept can be used broadly, for example depression and alcohol use disorder, or it can be restricted to specify severe mental illness (e.g. psychosis, schizophrenia) and substance use disorder (e.g. cannabis use), or a person who has a milder mental illness and a drug dependency, such as panic disorder or generalized anxiety disorder and is dependent on opioids. Diagnosing a primary psychiatric illness in people who use substances is challenging as substance use disorder itself often induces psychiatric symptoms, thus making it necessary to differentiate between substance induced and pre-existing mental illness. Those with co-occurring disorders face complex challenges. They have increased rates of relapse, hospitalization, homelessness, and HIV and hepatitis C infection compared to those with either mental or substance use disorders alone.
Sources: en.wikipedia.org
=== Pilonidal sinus === Pilonidal sinus (PNS): a sinus tract, or small channel, that may originate from the source of infection and open to the surface of the skin. Material from the cyst drains through the pilonidal sinus. A pilonidal cyst is usually painful, but if it is a draining sinus, the pressure is relieved and the patient might not feel pain.
== Product life cycle approach in validation == Validation process efforts must account for the complete product life cycle, including developmental procedures adapted for qualification of a drug product commencing with its research and development phase, rationale for adapting a best fit formula which represents the relationship between required outputs and specified inputs, and procedure for manufacturing. Each step is required to be justified and monitored in order to provide a good quality food and drug product. The FDA emphasizes the product life cycle approach in its evaluation of manufacturer regulatory compliance as well.
=== Marriage and family === Freeman was married to Jeanette Adair Bradshaw from October 22, 1967, until November 18, 1979. He married Myrna Colley-Lee on June 16, 1984, the couple separated in December 2007 and divorced on September 15, 2010. Freeman has four children: Alfonso, Deena, Morgana, and Saifoulaye. Freeman and Colley-Lee also raised Freeman's step-granddaughter from his first marriage, E'dena Hines. On August 16, 2015, 33-year-old Hines was murdered in New York City.
=== Malaria vaccine === In 2014, GSK applied for regulatory approval for the first malaria vaccine. Malaria is responsible for over 650,000 deaths annually, mainly in Africa. Known as RTS,S, the vaccine was developed as a joint project with the PATH vaccines initiative and the Bill and Melinda Gates Foundation. The company has committed to making the vaccine available in developing countries for five per cent above the cost of production. As of 2013, RTS,S, which uses GSK's proprietary AS01 adjuvant, was being examined in a Phase 3 trial in eight African countries. PATH reported that "[i]n the 12-month period following vaccination, RTS,S conferred approximately 50% protection from clinical Plasmodium falciparum disease in children aged 5-17 months, and approximately 30% protection in children aged 6-12 weeks when administered in conjunction with Expanded Program for Immunization (EPI) vaccines." In 2014, Glaxo said it had spent more than US$350 million and expected to spend an additional US$260 million before seeking regulatory approval.
== Sample preparation == Sample preparation is one of the most critical steps in NanoSIMS analysis, particularly when analysing biological samples. Specific protocols should be developed for individual experiments in order to best preserve not only the structure of the sample but also the true spatial distribution and abundance of molecules within the sample. As the NanoSIMS operates under ultra high vacuum, the sample must be vacuum compatible (i.e., volatile free), flat, which reduces varying ionization trajectories, and conductive, which can be accomplished by sputter coating with Au, Pt, or C. Biological samples, such as cells or tissue, can be prepared with chemical fixation or cryo-fixation and embedded in a resin before sectioning into thin slices (100 nm - 1μm), and placed on silicon wafers or slides for analysis. Sample preparation for metallographic samples is generally much simpler but a very good metallographic polish is required to achieve a flat, scratch free surface.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Dry powder is kept frozen, commonly at minus twenty degrees Celsius or below. It should be protected from light and moisture. Dissolved material is less stable and is generally used soon after preparation.